

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27779/36104	Serial No. 09/494,627
<b>INFORMATION DISCLOSURE STATEMENT</b>		Applicant Podolski, J.	
(Use several sheets if necessary)		Filing Date January 31, 2000	Group 1614

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	3,943,246	03/09/76	Sturmer, E.	424	177	
	A2	4,127,118	11/28/78	Latorre, A.	128	79	
	A4	4,139,617	02/13/79	Grunwell, J.F. <i>et al.</i>	424	248	
	A4	4,530,920	07/23/85	Nestor, J.J. <i>et al.</i>	514	15	
	A5	4,801,587	01/31/89	Voss, G. <i>et al.</i>	514	248	
	A9	4,863,911	09/05/89	Anderson, W.R. Jr. <i>et al.</i>	514	176	
	A7	4,885,173	12/05/89	Stanley, T.H. <i>et al.</i>	424	440	
	A9	5,059,603	10/22/91	Rubin, D.	514	264	
	A9	5,065,744	11/19/91	Zusmanovsky, Z.A.	128	79	
	A10	5,079,018	01/07/92	Ecanow, B.	426	309	
	A11	5,145,852	09/08/92	Virag, R.	514	253	
	A12	5,236,904	08/17/93	Gerstenberg, T. <i>et al.</i>	514	12	
	A13	5,256,652	10/26/93	El-Rashidy, R.	514	58	
	A14	5,270,323	12/14/93	Milne, G.M. Jr. <i>et al.</i>	514	309	
	A15	5,298,261	03/29/94	Pebbley, W.S. <i>et al.</i>	424	488	
	A16	5,399,581	03/21/95	Laragh, J.H. <i>et al.</i>	514	396	
	A17	5,565,466	10/15/96	Gioco, D.M. <i>et al.</i>	514	280	
	A18	5,731,339	03/24/98	Lowrey, F.	514	400	

EXAMINER /Alton Pryor/	DATE CONSIDERED 01/25/2010
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty Docket No. 27779/36104	Serial No. 09/494,627
<b>INFORMATION DISCLOSURE STATEMENT</b>		Applicant Podolski, J.	
(Use several sheets if necessary)		Filing Date January 31, 2000	Group 1614

FOREIGN PATENT DOCUMENTS							
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation
							Yes      No
	B1	0 357 581	3/7/90	EP			
	B2	WO 95/05172	02/23/95	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C1	AC-Di-Sol®, Croscarmellose Sodium, NF and Ph.Eur. The Premier Super Disintegrant For Wet and Dry Granulation Tablets And Capsules (Accelerates DisSolution) (Product Description Brochure); FMC Corporation, Philadelphia, PA, pp. 1-9 (1988).
	C2	Althof, S.E. et al., "Sexual, Psychological, and Marital Impact of Self-Injection of Papaverine and Phenotolamine: A Long-Term Prospective Study," <i>Journal Sex and Marital Therapy</i> , 17(2):101-112 (1991).
	C3	Azadzoi, K.M. et al., "Effects of Intracavernosal Trazadone Hydrochloride: Animal and Human Studies," <i>J. Urology</i> , 144(5):1277-1282 (November, 1990).
	C4	Barnett, A.J. et al., "The Action Of "Regitine" In Man With Special Reference To Its Adrenergic Blocking Action," <i>Australasian Annals of Medicine</i> , 1:109-119 (1952).
	C5	Beavo, J.A. et al., In: <i>Advances in Second Messenger and Phosphoprotein Research</i> , Greengard et al., (eds.), Volume 22, pgs. 1-38 (1988).
	C6	Biotechnology Newswatch, "Nice try, but no Viagra, say experts reviewing new potency pills," pp. 4-5 (June, 1998).
	C7	Brindley, G.S., "Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis," <i>Br. J. Pharmac.</i> , 87:495-500 (1986).
	C8	Brindley, G.S., "Cavernosal Alpha-Blockade: A New Technique for Investigating and Treating Erectile Impotence," <i>Brit. J. Psychiat.</i> , 143:332-337 (1983).

EXAMINER <i>/Alton Pryor/</i>	DATE CONSIDERED 01/25/2010
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
27779/36104Serial No.  
09/494,627

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Podolski, J.Filing Date  
January 31, 2000Group  
1614

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C9	Brindley, G.S., "Cavernosal alpha-blockade and human penile erection," <i>J. Physiol.</i> , 342:24P (1983).
C10	Corriere, J.N. Jr. et al., "Development of Fibrotic Penile Lesions Secondary to the Intracorporeal Injection of Vasoactive Agents," <i>J. Urology</i> , 140:615-617 (September, 1988).
C11	Dawson, A. et al., "The Transient Anti-Hypertensive Effect of Phentolamine in Patients Receiving Beta-Blocker Treatment," <i>J. Int. Med. Res.</i> , 5:462-464 (1977).
C12	Diedrichs, W. et al., "Reduction of Sympathetic Influence on Penile Erection by Phentolamine," <i>Urol. Int.</i> , 46:64-66 (1991).
C13	Georgopoulos, A.J. et al., "Treatment of Chronic Heart Failure with Slow Release Phentolamine," <i>Europ. J. Clin. Pharmacol.</i> , 13:325-329 (1978).
C14	Gissinger, D. et al., "A Comparative Evaluation of the Properties of some Tablet Disintegrant," <i>Drug Development and Industrial Pharmacy</i> , 6(5):511-536 (1980).
C15	Godbillon et al., "Determination of the Major Metabolite of Phentolamine in Human Plasma And Urine By High-Performance Liquid Chromatography," <i>J. Chromatography</i> , 222:461-466 (1981)
C16	Gould, L.A. et al., "Oral Therapy with Phentolamine in Chronic Congestive Heart Failure," <i>Chest</i> , 75(4):487-491 (April, 1979).
C17	Gwinup, G., "Oral Phentolamine in Nonspecific Erectile Insufficiency," <i>Annals Internal Medicine</i> , pgs. 162-163 (July, 1988).
C18	Imhof, P.R. et al., "Human Pharmacology of Orally Administered Phentolamine," In: Phentolamine in Heart Failure and Other Cardiac Disorders, Taylor, S.H., and Gould, L.A., (eds.), Ben Huber, pp. 11-22 (1976).
C19	Larsen, E.H. et al., "Fibrosis of Corpus Cavernosum After Intracavernous Injection of Phentolamine/Papaverine," <i>Journal Urology</i> , 137:292-293 (February, 1987).
C20	Marriot, H.J.L., "An Alarming Pressor Reaction To Regitine," 46(5):1001-1002 (May, 1957).

EXAMINER

/Alton Pryor/

DATE CONSIDERED

01/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No  
27779/36104Serial No  
09/494,627

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Podolski, J.Filing Date  
January 31, 2000Group  
1614

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C21	McDonnell, S.M. et al., "Imipramine-induced Erection, Masturbation, and Ejaculation in Male Horses," <i>Pharmacol. Biochem. Behav. (USA)</i> , 27(1):187-191 (May, 1987) ( <i>ABSTRACT</i> ).
C22	Montorsi, F. et al., "Clinical Reliability of Multi-Drug Intracavernous Vasoactive Pharmacotherapy for Diabetic Impotence," <i>Acta Diabetol.</i> , 31:1-5 (1994).
C23	NIH Consensus Conference, "Impotence," NIH Consensus Development Panel on Impotence, <i>Journal American Medical Association</i> , 270(1):83-90 (1993).
C24	Pfister et al., "Estimation of the Plasma Concentration and Course of Action of Phentol-amine Based On Its Inhibitory Effect On Adrenaline-Induced Platelet Aggregation," <i>Br. J. Clin. Pharmac.</i> , 5:175-180 (1978).
C25	<i>PHYSICIANS' DESK REFERENCE</i> , 37 Edition, pg. 409 and 864 (1983).
C26	Ruskin, J.N. et al., "Primary Pulmonary Hypertension Treated With Oral Phentolamine," <i>Annals of Internal Medicine</i> , 90:772-774 (1979).
C27	Schreiber, R. et al., "Hemodynamic Improvement following a Single Dose of Oral Phentolamine: Administration in Patients with Chronic Low Output Cardiac Failure," <i>Chest</i> , 76(5):571-575 (November, 1979).
C28	Selvaag, O. et al., "Experiences with Regitin (A New Vasodilator Compound)," <i>Acta Medica Scandinavica</i> , Vol. CXLVI, fase. III, pp. 209-215 (1953).
C29	Sioufi, A. et al., "Gas Chromatographic Determination of Phenentolamine (Regitine) in Human Plasma and Urine," <i>Journal of Chromatography</i> , 222:429-435 (1981).
C30	Sonda, L.P. et al., "The Role of Yohimbine for the Treatment of Erectile Impotence," <i>J. Sex &amp; Marital Ther.</i> , 16(1):15-21 (1990).
C31	Terrett, N.K. et al., "Sildenafil (VIAGRA™), A Potent and Selective Inhibitor of Type 5 cGMP Phosphodiesterase with Utility for the Treatment of Male Erectile Dysfunction," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 6(15):1819-1824 (1996).
C32	<i>The Extra Pharmacopoeia: The authoritative reference work on drugs and medicines in current use</i> , Twenty-sixth Edition, 2 pages (1988).

EXAMINER	/Alton Pryor/	DATE CONSIDERED	01/25/2010
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No  
27779/36104Serial No  
09/494,627**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant  
Podolski, J.Filing Date  
January 31, 2000Group  
1614**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

C33	Trapold, J.H. et al., "Pharmacological and Toxicological Studies on 2-(N-p'tolyl-N-(m'-Hydroxypheyl)-Aminomethyl)-Imidazoline (C-7337), a New Adrenergic Blocking Agent " pp. 119-127 (1950).
C33	<i>United States Pharmacopeia</i> , Twentieth Revision, Official from July 1, 1980, The National Formulary, Fifteenth Edition, Official from July 1, 1980, United States Pharmacopeial Convention, Inc., Rockville, Maryland, pp. 615-617 (1979).
C35	Virag, R. et al., "Intracavernous Injection of Papaverine as a Diagnostic and Therapeutic Method in Erectile Failure," <i>Angiology</i> , 35:79-87 (1984).
C36	Virag, R., "Intracavernous Injection of Papaverine for Erectile Failure," <i>Lancet</i> , ii:938 (October, 1982).
C37	Wagner, G. et al., "Buccal Phentolamine-A pilot trial for male erectile dysfunction at three separate clinics," <i>Int. J. Impotence Res.</i> , 6(Suppl. 1):D78 (1994).
C38	Williams, <i>Textbook of Endocrinology</i> , p. 313 (Circa, 1976).
C39	Zorgniotti, A.W., "'On Demand' Oral Drug For Erection In Impotent Men," <i>J. Urology (AUA Eighty-Seventh Annual Meeting May 10-14, 1992)</i> , 147(4)(Suppl.):308A (April, 1992) (ABSTRACT 382).
C40	Zorgniotti, A.W., "Experience with Buccal Phentolamine Mesylate for Impotence," <i>International Journal of Impotence Research</i> , 6(1):37-41 (March, 1994).
C41	Zorgniotti, A.W. et al., "Auto-injection of the Corpus Cavernosum with a Vasoactive Drug Combination for Vascularogenic Impotence," <i>Journal Urology</i> , 133:39-41 (1985).

EXAMINER

/Alton Pryor/

DATE CONSIDERED

01/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.